EUMETSAT
14.12.2022 10:45:38 CET | Business Wire | Press release
Tonight’s launch of a highly advanced meteorological satellite from, Kourou, French Guiana, heralds the start of a new era for weather forecasting in Europe, EUMETSAT Director-General Phil Evans said.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005463/en/
MTG-I1 is successfully launched on an Ariane-5 rocket from Kourou, French Guiana (Photo: EUMETSAT)
The satellite, MTG-I1, is the first of a new generation of meteorological satellites carrying more advanced and precise instruments for monitoring and forecasting severe weather events such as storms, lightning, fog and wildfires.
It was successfully launched on an Ariane-5 rocket at 21:30 CET and is on its way to its correct orbit, 36,000km above the Equator.
“MTG-I1 will generate images of Europe and Africa every 10 minutes, faster than has been possible up until now, and in higher resolution, more precise detail,” Evans said.
“This data will help meteorologists meet one of their main challenges – timely and accurate forecasts of rapidly developing severe weather events – so that citizens, first responders and civil authorities can take appropriate action.
“The satellite’s lightning imager will continuously map lightning flashes between clouds and from clouds to the ground, which is a first for Europe with significant community and aviation industry safety benefits.”
MTG-I1 – full name Meteosat Third Generation – Imager 1 – will undergo a 12-month commissioning phase, in which its instruments will be calibrated and the data they produce validated, before becoming operational.
It will be operated from EUMETSAT’s headquarters in Darmstadt, Germany.
“Meteosat Third Generation is a European success story,” Evans said. “No European nation could afford to develop and operate such a system on its own. By combining the resources of our 30 member states, including their scientific and technical expertise, we are able to bring about a new era in weather and climate monitoring.”
More information about MTG-I1 can be found here.
Brochure containing facts and figures and other information about the MTG system can be found here.
The full Meteosat Third Generation constellation will comprise two imaging satellites and, for the first time, a sounding satellite. MTG – Sounder 1, is expected to be launched in 2024.
MTG-I1 was built by Thales Alenia Space under contract by the European Space Agency (ESA). ESA is responsible for procuring the satellites from industry fulfilling EUMETSAT’s requirements.
Thales Alenia Space Cannes is the prime industrial partner for the development of the MTG-I satellites. TAS works in close cooperation with:
• OHB-Bremen, which assembled, integrated and tested the platform
• LEONARDO in Italy, which provided the Lightning Imager instrument
• Thales Alenia Space Italy, which delivered the Data Collection and GEO SAR instruments
• Thales Alenia Space Cannes also integrated the Flexible Combined Imager.
For more information, visit the EUMETSAT website.
About EUMETSAT
EUMETSAT, Europe’s meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.
Three Meteosat Second Generation satellites in geostationary orbit deliver continuous observations of fast developing severe weather events over Europe, Africa and the Indian Ocean. The first of the Meteosat Third Generation satellites was launched in December 2022 and will undergo 12 months’ in-orbit commissioning. Two polar-orbiting Metop satellites provide data of pivotal importance for forecasts up to 10 days ahead. The first of the second-generation Metop satellites is expected to be launched in 2025.
EUMETSAT’s archive of satellite observations over more than 40 years provides climate scientists around the world with long-term, homogenous data necessary for monitoring climate change.
EUMETSAT is a key partner in the European Union’s Copernicus Earth observation programme. It operates the Copernicus Sentinel-3 and -6 ocean-monitoring missions, and will operate the upcoming CO2M mission, to monitor carbon dioxide emissions. EUMETSAT will fly the Copernicus Sentinel-4 and -5 missions on board its own MTG and Metop-SG satellites. Data from these Sentinels, and EUMETSAT’s own missions, are provided to the Copernicus climate, atmosphere monitoring and marine environment services. Along with European Space Agency and the European Centre for Medium-Range Weather Forecasts, EUMETSAT is a partner in the EU’s DestinE initiative, creating digital twins of the entire Earth system.
Together with NASA, NOAA, the EU, ESA and with support from the French Space Agency, CNES, EUMETSAT is a partner in the Jason and Copernicus Sentinel-6 ocean-monitoring missions.
EUMETSAT cooperates with agencies around the world, securing additional satellite data of benefit to weather forecasting and climate monitoring.
EUMETSAT’s 30 member states are: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005463/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
